Adenovirus-mediated gene delivery: Potential applications for gene and cell-based therapies in the new era of personalized medicine

Genes and Diseases

Volumn 4, Issue 2, 2017, Pages 43-63

  Lee, Cody S ^a,b,c   Bishop, Elliot S ^b   Zhang, Ruyi ^c,d   Yu, Xinyi ^c,d   Farina, Evan M ^a,b,c   Yan, Shujuan ^c,d   Zhao, Chen ^c,d   Zeng, Zongyue ^c,d   Shu, Yi ^c,d   Wu, Xingye ^c,d   Lei, Jiayan ^c,d   Li, Yasha ^c,d   Zhang, Wenwen ^c,e   Yang, Chao ^c,d   Wu, Ke ^c,d   Wu, Ying ^c,f   Ho, Sherwin ^c   Athiviraham, Aravind ^c   Lee, Michael J ^c   Wolf, Jennifer Moriatis ^c   Reid, Russell R ^b   He, Tong Chuan ^c   more..

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^c NY   (United States)

^d CHONGQING MEDICAL UNIVERSITY   (China)

^e BINZHOU MEDICAL UNIVERSITY   (China)

^f BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Adenoviral vector; Adenovirus; Cell therapy; Gene therapy; Gene transfer; Oncolytic virus; Regenerative medicine; Vaccine development

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; LENTIVIRUS VECTOR; VACCINE; VIRUS DNA;

ADENO ASSOCIATED VIRUS; ADENOVIRIDAE; CANCER THERAPY; CELL THERAPY; CLINICAL STUDY; DNA FOOTPRINTING; DRUG SAFETY; EPISOME; GENE THERAPY; GENE TRANSFER; GENETIC ENGINEERING; HERPES SIMPLEX VIRUS; HUMAN; LARGE CARGO GENE DELIVERY; MOLECULAR EVOLUTION; MONOGENIC DISORDER; NERVOUS TISSUE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRECLINICAL STUDY; REGENERATIVE MEDICINE; REVIEW; SMALL CARGO GENE DELIVERY; TRANSPOSON; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

EID: 85019161821     PISSN: 23524820     EISSN: 23523042     Source Type: Journal    
DOI: 10.1016/j.gendis.2017.04.001     Document Type: Review

References (253)

1. Kay, M.A., Glorioso, J.C., Naldini, L., Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 7:1 (2001), 33–40.
2. Crystal, R.G., Adenovirus: the first effective in vivo gene delivery vector. Hum Gene Ther 25:1 (2014), 3–11.
3. Breyer, B., Jiang, W., Cheng, H., et al. Adenoviral vector-mediated gene transfer for human gene therapy. Curr Gene Ther 1:2 (2001), 149–162.
4. Seymour, L.W., Fisher, K.D., Adenovirus: teaching an old dog new tricks. Hum Gene Ther 22:9 (2011), 1041–1042.
5. Rauschhuber, C., Noske, N., Ehrhardt, A., New insights into stability of recombinant adenovirus vector genomes in mammalian cells. Eur J Cell Biol 91:1 (2012), 2–9.
6. Jin, L., Zeng, X., Liu, M., Deng, Y., He, N., Current progress in gene delivery technology based on chemical methods and nano-carriers. Theranostics 4:3 (2014), 240–255.
7. Wang, W., Li, W., Ma, N., Steinhoff, G., Non-viral gene delivery methods. Curr Pharm Biotechnol 14:1 (2013), 46–60.
8. Manjila, S.B., Baby, J.N., Bijin, E.N., Constantine, I., Pramod, K., Valsalakumari, J., Novel gene delivery systems. Int J Pharm Investig 3:1 (2013), 1–7.
9. Nayerossadat, N., Maedeh, T., Ali, P.A., Viral and nonviral delivery systems for gene delivery. Adv Biomed Res, 1, 2012, 27.
10. Katare, D.P., Aeri, V., Progress in gene therapy: a review. Int J Toxicol Pharm Res 1:2 (2010), 33–41.
11. Gardlík, R., Pálffy, R., Hodosy, J., Lukács, J., Turna, J., Celec, P., Vectors and delivery systems in gene therapy. Med Sci Monit 11:4 (2005), RA110–121.
12. Robertson, E.S., Ooka, T., Kieff, E.D., Epstein-Barr virus vectors for gene delivery to B lymphocytes. Proc Natl Acad Sci U S A 93:21 (1996), 11334–11340.
13. Hirai, H., Satoh, E., Osawa, M., et al. Use of EBV-based Vector/HVJ-liposome complex vector for targeted gene therapy of EBV-associated neoplasms. Biochem Biophys Res Commun 241:1 (1997), 112–118.
14. Ohe, Y., Zhao, D., Saijo, N., Podack, E.R., Construction of a novel bovine papillomavirus vector without detectable transforming activity suitable for gene transfer. Hum Gene Ther 6:3 (1995), 325–333.
15. Verma, I.M., Somia, N., Gene therapy – promises, problems and prospects. Nature 389:6648 (1997), 239–242.
16. Mountain, A., Gene therapy: the first decade. Trends Biotechnol 18:3 (2000), 119–128.
17. Luo, D., Saltzman, W.M., Synthetic DNA delivery systems. Nat Biotechnol 18:1 (2000), 33–37.
18. Doerfler, W., Schubbert, R., Heller, H., Integration of foreign DNA and its consequences in mammalian systems. Trends Biotechnol 15:8 (1997), 297–301.
19. Garrick, D., Fiering, S., Martin, D.I., Whitelaw, E., Repeat-induced gene silencing in mammals. Nat Genet 18:1 (1998), 56–59.
20. Remus, R., Heller, H., Schmitz, B., Schell, G., Doerfler, W., Kämmer, C., Insertion of foreign DNA into an established mammalian genome can alter the methylation of cellular DNA sequences. J Virol 73:2 (1999), 1010–1022.
21. Ehrhardt, A., Haase, R., Schepers, A., Deutsch, M.J., Lipps, H.J., Baiker, A., Episomal vectors for gene therapy. Curr Gene Ther 8:3 (2008), 147–161.
22. Van Craenenbroeck, K., Vanhoenacker, P., Haegeman, G., Episomal vectors for gene expression in mammalian cells. Eur J Biochem 267:18 (2000), 5665–5678.
23. Belt, P.B., Jongmans, W., de Wit, J., Hoeijmakers, J.H., van de Putte, P., Backendorf, C., Efficient cDNA cloning by direct phenotypic correction of a mutant human cell line (HPRT-) using an Epstein-Barr virus-derived cDNA expression vector. Nucleic Acids Res 19:18 (1991), 4861–4866.
24. Mazda, O., Satoh, E., Yasutomi, K., Imanishi, J., Extremely efficient gene transfection into lympho-hematopoietic cell lines by Epstein-Barr virus-based vectors. Methods 204:2 (1997), 143–151.
25. Friedrich, T.D., Bedner, E., Darzynkiewicz, Z., Lehman, J.M., Distinct patterns of MCM protein binding in nuclei of S phase and rereplicating SV40-infected monkey kidney cells. Cytom Part Soc Anal Cytol 68:1 (2018), 10–18.
26. Valls, E., de la Cruz, X., Martínez-Balbás, M.A., The SV40 T antigen modulates CBP histone acetyltransferase activity. Nucleic Acids Res 31:12 (2003), 3114–3122.
27. Darimont, C., Zbinden, I., Avanti, O., Reconstitution of telomerase activity combined with HPV-E7 expression allow human preadipocytes to preserve their differentiation capacity after immortalization. Cell Death Differ 10:9 (2003), 1025–1031.
28. Harris, K.F., Christensen, J.B., Imperiale, M.J., BK virus large T antigen: interactions with the retinoblastoma family of tumor suppressor proteins and effects on cellular growth control. J Viol 70:4 (1996), 2378–2386.
29. Liu, H., Visner, G.A., Applications of Sleeping Beauty transposons for nonviral gene therapy. IUBMB Life 59:6 (2007), 374–379.
30. Ehrhardt, A., Xu, H., Huang, Z., Engler, J.A., Kay, M.A., A direct comparison of two nonviral gene therapy vectors for somatic integration: in vivo evaluation of the bacteriophage integrase phiC31 and the Sleeping Beauty transposase. Mol Ther 11:5 (2005), 695–706.
31. Muñoz-López, M., García-Pérez, J.L., DNA transposons: nature and applications in genomics. Curr Genomics 11:2 (2010), 115–128.
32. Hackett, P.B., Aronovich, E.L., Hunter, D., Efficacy and safety of Sleeping Beauty transposon-mediated gene transfer in preclinical animal studies. Curr Gene Ther 11:5 (2011), 341–349.
33. Skipper, K.A., Andersen, P.R., Sharma, N., Mikkelsen, J.G., DNA transposon-based gene vehicles-scenes from an evolutionary drive. J Biomed Sci, 20, 2013.
34. Ivics, Z., Izsvák, Z., Sleeping beauty transposition. Microbiol Spectr, 3(2), 2015 MDNA3-0042-2014.
35. Wang, D., Gao, G., State-of-the-art human gene therapy: part I. Gene Deliv Technol Discov Med 18:97 (2014), 67–77.
36. Grabundzija, I., Irgang, M., Mátés, L., Comparative analysis of transposable element vector systems in human cells. Mol Ther 18:6 (2010), 1200–1209.
37. Plasterk, R.H., Molecular mechanisms of transposition and its control. Cell 74:5 (1993), 781–786.
38. Ivics, Z., Izsvák, Z., Transposons for gene therapy!. Curr Gene Ther 6:5 (2006), 593–607.
39. Chen, X., Cui, J., Yan, Z., et al. Sustained high level transgene expression in mammalian cells mediated by the optimized piggyBac transposon system. Genes Dis 2:1 (2015), 96–105.
40. Yant, S.R., Park, J., Huang, Y., Mikkelsen, J.G., Kay, M.A., Mutational analysis of the N-terminal DNA-binding domain of sleeping beauty transposase: critical residues for DNA binding and hyperactivity in mammalian cells. Mol Cell Biol 24:20 (2004), 9239–9247.
41. Sakuma, T., Barry, M.A., Ikeda, Y., Lentiviral vectors: basic to translational. Biochem J 443:3 (2012), 603–618.
42. Ertl, H.C.J., Progress in the development of hepatitis C virus vaccines. Mol Ther 20:4 (2012), 697–698.
43. Lachmann, R.H., Efstathiou, S., The use of herpes simplex virus-based vectors for gene delivery to the nervous system. Mol Med Today 3:9 (1997), 404–411.
44. Federici, T., Kutner, R., Zhang, X.Y., et al. Comparative analysis of HIV-1-based lentiviral vectors bearing lyssavirus glycoproteins for neuronal gene transfer. Genet Vaccines Ther, 7, 2009, 1.
45. Hacein-Bey-Abina, S., Hauer, J., Lim, A., et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 363:4 (2010), 355–364.
46. Anson, D.S., The use of retroviral vectors for gene therapy-what are the risks? A review of retroviral pathogenesis and its relevance to retroviral vector-mediated gene delivery. Genet Vaccines Ther, 2(1), 2004 1479-0556.
47. Laufs, S., Gentner, B., Nagy, K.Z., Retroviral vector integration occurs in preferred genomic targets of human bone marrow-repopulating cells. Blood 101:6 (2002), 2191–2198.
48. Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302:5644 (2003), 415–419.
49. Hacein-Bey-Abina, S., Le Deist, F., Carlier, F., et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 346:16 (2002), 1185–1193.
50. Fischer, A., Hacein-Bey-Abina, S., Lagresle, C., Garrigue, A., Cavazana-Calvo, M., Gene therapy of severe combined immunodeficiency disease: proof of principle of efficiency and safety issues. Gene therapy primary immunodeficiencies retrovirus lentivirus genome. Bull Acad Natl Med 189:5 (2005), 779–785 discussion 786–788.
51. Fox, J.L., US authorities uphold suspension of SCID gene therapy. Nat Biotechnol, 21(3), 2003, 217.
52. Buckley, R.H., Gene therapy for SCID-a complication after remarkable progress. Lancet 360:9341 (2002), 1185–1186.
53. Wu, X., Burgess, S.M., Sci, C., Integration target site selection for retroviruses and transposable elements. Cell Mol Life, 2004, 19–20.
54. Cereseto, A., Giacca, M., Integration site selection by retroviruses. AIDS Rev 6:1 (2004), 13–21.
55. Engelman, A., The roles of cellular factors in retroviral integration. Curr Top Microbiol Immunol 281 (2003), 209–238.
56. Cockrell, A.S., Kafri, T., Gene delivery by lentivirus vectors. Mol Biotechnol 36:3 (2007), 184–204.
57. Kafri, T., Clifton, N.J., Gene delivery by lentivirus vectors an overview. Methods Mol Biol 246 (2004), 367–390.
58. Balaggan, K.S., Ali, R.R., Ocular gene delivery using lentiviral vectors. Gene Ther 19:2 (2011), 145–153.
59. Wong, L., Goodhead, L., Prat, C., Mitrophanous, K.A., Kingsman, S.M., Mazarakis, N.D.F., Lentivirus-mediated gene transfer to the central nervous system: therapeutic and research applications. Hum Gene Ther 17:1 (2006), 1–9.
60. Azzouz, M., Martin-Rendon, E., Barber, R.D., Multicistronic lentiviral vector-mediated striatal gene transfer of aromatic L-amino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase I induces sustained transgene expression, dopamine production, and functional improvement in a rat model of Parkinson's disease. J Neurosci 22:23 (2002), 10302–10312.
61. Betchen, S.A., Kaplitt, M., Future and current surgical therapies in Parkinson's disease. Curr Opin Neurol 16:4 (2003), 487–493.
62. Vannucci, L., Lai, M., Chiuppesi, F., Ceccherini-Nelli, L., Pistello, M., Viral vectors: a look back and ahead on gene transfer technology. New Microbiol 36:1 (2013), 1–22.
63. Dropulić, B., Lentiviral vectors: their molecular design, safety, and use in laboratory and preclinical research. Hum Gene Ther 22:6 (2011), 649–657.
64. Howarth, J.L., Lee, Y.B., Uney, J.B., Using viral vectors as gene transfer tools (Cell Biology and Toxicology Special Issue: ETCS-UK 1 day meeting on genetic manipulation of cells). Cell Biol Toxicol 26:1 (2010), 1–20.
65. Mátrai, J., Chuah, M.K., VandenDriessche, T., Recent advances in lentiviral vector development and applications. Mol Ther 18:3 (2010), 477–490.
66. Samulski, R.J., Muzyczka, N., AAV-mediated gene therapy for research and therapeutic purposes. Annu Rev Virol 1:1 (2014), 427–451.
67. Balakrishnan, B., Jayandharan, G.R., Basic biology of adeno-associated virus (AAV) vectors used in gene therapy. Curr Gene Ther 14:2 (2014), 86–100.
68. Waehler, R., Russell, S.J., Curiel, D.T., Engineering targeted viral vectors for gene therapy. Nat Rev Genet 8:8 (2007), 573–587.
69. Nayak, S., Herzog, R.W., Progress and prospects: immune responses to viral vectors. Gene Ther 17:3 (2009), 295–304.
70. McCarty, D.M., Monahan, P.E., Samulski, R.J., Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther 8:16 (2001), 1248–1254.
71. Walther, W., Stein, U., Viral vectors for gene transfer: a review of their use in the treatment of human diseases. Drugs 60:2 (2000), 249–271.
72. Teramato, S., Ishii, T., Matsuse, T., Crisis of adenoviruses in human gene therapy. Lancet 355:9218 (2000), 1911–1912.
73. Giacca, M., Zacchigna, S., Virus-mediated gene delivery for human gene therapy. J Control Release 161:2 (2012), 377–388.
74. Smith, R.H., Adeno-associated virus integration: virus versus vector. Gene Ther 15:11 (2008), 817–822.
75. Flotte, T.R., Birth of a new therapeutic platform: 47 years of adeno-associated virus biology from virus discovery to licensed gene therapy. Mol Ther 21:11 (2013), 1976–1981.
76. Lai, C.M., Lai, Y.K., Rakoczy, P.E., Adenovirus and adeno-associated virus vectors. DNA Cell Biol 21:12 (2002), 895–913.
77. Flotte, T., Carter, B., Conrad, C., A phase I study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease. Hum Gene Ther 7:9 (1996), 1145–1159.
78. Kay, M.A., Manno, C.S., Ragni, M.V., Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 24:3 (2000), 257–261.
79. Duque, S., Joussemet, B., Riviere, C., Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther 17:7 (2009), 1187–1196.
80. Foust, K.D., Nurre, E., Montgomery, C.L., Hernandez, A., Chan, C.M., Kaspar, B.K., Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 27:1 (2009), 59–65.
81. Yang, B., Li, S., Wang, H., et al. Global CNS transduction of adult mice by intravenously delivered rAAVrh.8 and rAAVrh.10 and nonhuman primates by rAAVrh.10. Mol Ther 22:7 (2014), 1299–1309.
82. Zhang, H., Yang, B., Mu, X., Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system. Mol Ther 19:8 (2011), 1440–1448.
83. Nagabhushan Kalburgi, S., Khan, N.N., Gray, S.J., Recent gene therapy advancements for neurological diseases. Discov Med 15:81 (2013), 111–119.
84. Lachmann, R., J. Herpes simplex virus-based vectors. Int Pathol 85:4 (2004), 177–190.
85. Hukkanen, V., Herpesvirus vectors in gene therapy. Open Virol J 4 (2010), 94–95.
86. Liu, W., Liu, Z., Liu, L., A novel human foamy virus mediated gene transfer of GAD67 reduces neuropathic pain following spinal cord injury. Neurosci Lett 432:1 (2007), 13–18.
87. Burton, E.A., Fink, D.J., Glorioso, J.C., Gene delivery using herpes simplex virus vectors. DNA Cell Biol 21:12 (2002), 915–936.
88. Lentz, T.B., Gray, S.J., Samulski, R.J., Viral vectors for gene delivery to the central nervous system. Neurobiol Dis 48:2 (2011), 179–188.
89. de Silva, S., Bowers, W.J., Herpes virus amplicon vectors. Viruses 1:3 (2009), 594–629.
90. Marconi, P., Argnani, R., Epstein, A.L., Manservigi, R., HSV as a vector in vaccine development and gene therapy. Adv Exp Med Biol 655 (2009), 118–144.
91. Marconi, P., Manservigi, R., Epstein, A.L., HSV-1-derived helper-independent defective vectors, replicating vectors and amplicon vectors, for the treatment of brain diseases. Curr Opin Drug Discov Devel 13:2 (2010), 169–183.
92. Manservigi, R., Argnani, R., Marconi, P., HSV recombinant vectors for gene therapy. Open Virol J 4 (2010), 123–156.
93. Goss, J.R., Krisky, D., Wechuck, J., Wolfe, D., Herpes simplex virus-based nerve targeting gene therapy in pain management. J Pain Res 7 (2014), 71–79.
94. Agarwalla, P.K., Aghi, M.K., Clifton, N.J., Oncolytic herpes simplex virus engineering and preparation. Methods Mol Biol 797 (2012), 1–19.
95. Berto, E., Bozac, A., Marconi, P., Development and application of replication-incompetent HSV-1-based vectors. Gene Ther 1:12 Suppl (2005), S98–S102.
96. Burton, E.A., Wechuck, J.B., Wendell, S.K., Goins, W.F., Fink, D.J., Glorioso, J.C., Multiple applications for replication-defective herpes simplex virus vectors. Stem Cells 19:5 (2001), 358–377.
97. Goins, W.F., Goss, J.R., Chancellor, M.B., de Groat, W.C., Glorioso, J.C., Yoshimura, N., Herpes simplex virus vector-mediated gene delivery for the treatment of lower urinary tract pain. Gene Ther 16:4 (2009), 558–569.
98. Wolfe, D., Mata, M., Fink, D.J., A human trial of HSV-mediated gene transfer for the treatment of chronic pain. Gene Ther 16:4 (2009), 455–460.
99. Goss, J.R., Harley, C.F., Mata, M., et al. Herpes vector-mediated expression of proenkephalin reduces bone cancer pain. Ann Neurol 52:5 (2002), 662–665.
100. Pulkkanen, K.J., Yla-Herttuala, S., Gene therapy for malignant glioma: current clinical status. Mol Ther 12:4 (2005), 585–598.
101. Wong, J., Lee, C., Zhang, K., Rennie, P.S., Jia, W., Targeted oncolytic herpes simplex viruses for aggressive cancers. Curr Pharm Biotechnol 13:9 (2012), 1786–1794.
102. Davison, A.J., Benko, M., Harrach, B., Genetic content and evolution of adenoviruses. J Gen Virol 84:Pt 11 (2003), 2895–2908.
103. Lasaro, M.O., Ertl, H.C.J., New insights on adenovirus as vaccine vectors. Mol Ther 17:8 (2009), 1333–1339.
104. Lehrman, S., Virus treatment questioned after gene therapy death. Nature 401:6753 (1999), 517–518.
105. Bett, A.J., Prevec, L., Graham, F.L., Packaging capacity and stability of human adenovirus type 5 vectors. J Virol 67:10 (1993), 5911–5921.
106. Reid, T., Warren, R., Kirn, D., Intravascular adenoviral agents in cancer patients: lessons from clinical trials. Cancer Gene Ther 9:12 (2002), 979–986.
107. Raper, S.E., Chirmule, N., Lee, F.S., Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 80:1-2 (2003), 148–158.
108. Marshall, E., Gene therapy death prompts review of adenovirus vector. Science 286:5448 (1999), 2244–2245.
109. Choi, I.K., Yun, C.O., Recent developments in oncolytic adenovirus-based immunotherapeutic agents for use against metastatic cancers. Cancer Gene Ther 20:2 (2013), 70–76.
110. Russell, S.J., Peng, K.W., Bell, J.C., Oncolytic virotherapy. Nat Biotechnol 30:7 (2012), 658–670.
111. Cerullo, V., Pesonen, S., Diaconu, I., Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res 70:11 (2010), 4297–4309.
112. Kaufmann, J.K., Nettelbeck, D.M., Virus chimeras for gene therapy, vaccination, and oncolysis: adenoviruses and beyond. Trends Mol Med 18:7 (2012), 365–376.
113. Ramos-Kuri, M., Rapti, K., Mehel, H., Dominant negative Ras attenuates pathological ventricular remodeling in pressure overload cardiac hypertrophy. Biochim Biophys Acta 1853:11 Pt A (2015), 2870–2884.
114. Vorburger, S.A., Hunt, K.K., Adenoviral gene therapy. Oncologist 7:1 (2002), 46–59.
115. Parks, R.J., Chen, L., Anton, M., Sankar, U., Rudnicki, M.A., Graham, F.L., A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci U S A 93:24 (1996), 13565–13570.
116. Sandig, V., Youil, R., Bett, A.J., Franlin, L.L., Oshima, M., Maione, D., Optimization of the helper-dependent adenovirus system for production and potency in vivo. Proc Natl Acad Sci U S A 97:3 (2000), 1002–1007.
117. Reddy, P., Viii, A., Sustained human factor in hemophilia following systemic delivery of a gutless adenoviral vector. Mol Ther 5:1 (2002), 63–73.
118. Ng, P., Development of a FLP/frt system for generating helper-dependent adenoviral vectors. Mol Ther 3:5 (2001), 809–815.
119. Medico, E., Gambarotta, G., Gentile, A., Comoglio, P.M., Soriano, P., A gene trap vector system for identifying transcriptionally responsive genes. Nat Biotechnol 19:6 (2001), 579–582.
120. Kalburgi, S., Khan, N.N., Gray, S.J., Nagabhushan Recent gene therapy advancements for neurological diseases. Discov Med 15:81 (2013), 111–119.
121. He, T.C., Adenoviral vectors. Curr Protoc Hum Genet, 2004, 12.4.1–12.4.25 Chapter 12: Unit 12–14.
122. He, T.C., Zhou, S., da Costa, L.T., Yu, J., Kinzler, K.W., Vogelstein, B., A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A 95:5 (1998), 2509–2514.
123. Mizuguchi, H., Kay, M.A., Hayakawa, T., Approaches for generating recombinant adenovirus vectors. Adv Drug Deliv Rev 52:3 (2001), 165–176.
124. Danthinne, X., Imperiale, M.J., Production of first generation adenovirus vectors: a review. Gene Ther 7:20 (2000), 1707–1714.
125. Luo, J., Deng, Z.L., Luo, X., et al. A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. Nat Protoc 2:5 (2007), 1236–1247.
126. Berkner, K.L., Sharp, P.A., Generation of adenovirus by transfection of plasmids. Nucleic Acids Res 11:17 (1983), 6003–6020.
127. Mizuguchi, H., Kay, M.A., Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. Hum Gene Ther 9:17 (1998), 2577–2583.
128. Hardy, S., Kitamura, M., Harris-Stansil, T., Dai, Y., Phipps, M.L., Construction of adenovirus vectors through Cre-lox recombination. J Virol 71:3 (1997), 1842–1849.
129. Ng, P., Evelegh, C., Cummings, D., Graham, F.L., Cre levels limit packaging signal excision efficiency in the Cre/lox Adenoviral vector system. J Virol 76:9 (2002), 4181–4189.
130. Ketner, G., Spencer, F., Tugendreich, S., Connelly, C., Hieter, P., Efficient manipulation of the human adenovirus genome as an infectious yeast artificial chromosome clone. Proc Natl Acad Sci U S A 91:13 (1994), 6186–6190.
131. Chartier, C., Degryse, E., Gantzer, M., Dieterle, A., Pavirani, A., Mehtali, M., Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J Virol 70:7 (1996), 4805–4810.
132. Crouzet, J., Naudin, L., Orsini, C., et al. Recombinational construction in Escherichia coli of infectious adenoviral genomes. Proc Natl Acad Sci U S A 94:4 (1997), 1414–1419.
133. Umana, P., Gerdes, C.A., Stone, D., et al. Efficient FLPe recombinase enables scalable production of helper-dependent adenoviral vectors with negligible helper-virus contamination. Nat Biotechnol 19:6 (2001), 582–585.
134. Zhao, C., Wu, N., Deng, F., et al. Adenovirus-mediated gene transfer in mesenchymal stem cells can be significantly enhanced by the cationic polymer polybrene. PLoS One, 9(3), 2014, e92908.
135. Wu, N., Zhang, H., Deng, F., et al. Overexpression of Ad5 precursor terminal protein accelerates recombinant adenovirus packaging and amplification in HEK-293 packaging cells. Gene Ther 21:7 (2014), 629–637.
136. Wei, Q., Fan, F., Liao, J., et al. Engineering the rapid adenovirus production and amplification (RAPA) cell line to expedite the generation of recombinant adenoviruses. Cell Physiol Biochem 41 (2017), 2383–2398.
137. Jaffe, H.A., Danel, C., Longenecker, G., Adenovirus-mediated in vivo gene transfer and expression in normal rat liver. Nat Genet 1:5 (1992), 372–378.
138. Rosenfeld, M.A., Yoshimura, K., Trapnell, B.C., In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 68:1 (1992), 143–155.
139. Yang, Y., Nunes, F.A., Berencsi, K., Furth, E.E., Gönczöl, E., Wilson, J.M., Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U S A 91:10 (1994), 4407–4411.
140. Yang, Y., Jooss, K.U., Su, Q., Ertl, H.C., Wilson, J.M., Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther 3:2 (1996), 137–144.
141. Kotterman, M.A., Chalberg, T.W., Schaffer, D.V., Viral vectors for gene therapy: translational and clinical outlook. Annu Rev Biomed Eng 17 (2015), 63–89.
142. Ginn, S.L., Alexander, I.E., Edelstein, M.L., Abedi, M.R., Wixon, J., Gene therapy clinical trials worldwide to -an update. J Gene Med 15:2 (2013), 65–77.
143. Wu, Q., Xia, D., Carlsen, S., Xiang, J., Adenovirus-mediated transgene-engineered dendritic cell vaccine of cancer. Curr Gene Ther 5:2 (2005), 237–247.
144. Tagawa, M., Kawamura, K., Ueyama, T., Cancer therapy with local oncolysis and topical cytokine secretion. Front Biosci Libr 13 (2008), 2578–2587.
145. Matthews, K.S., Alvarez, R.D., Curiel, D.T., Advancements in adenoviral based virotherapy for ovarian cancer. Adv Drug Deliv Rev 61:10 (2009), 836–841.
146. Fukazawa, T., Matsuoka, J., Yamatsuji, T., et al. Adenovirus-mediated cancer gene therapy and virotherapy (Review). Int J Mol Med 25:1 (2010), 3–10.
147. Aguilar, L.K., Guzik, B.W., Aguilar-Cordova, E., Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development. J Cell Biochem 112:8 (2011), 1969–1977.
148. Aurisicchio, L., Ciliberto, G., Genetic cancer vaccines: current status and perspectives. Expert Opin Biol Ther 12:8 (2012), 1043–1058.
149. Duarte, S., Carle, G., Faneca, H., de Lima, M.C.P., Pierrefite-Carle, V., Suicide gene therapy in cancer: where do we stand now?. Cancer Lett 324:2 (2012), 160–170.
150. Deisseroth, A., Tang, Y., Zhang, L., Akbulut, H., Habib, N., TAA/ecdCD40L adenoviral prime-protein boost vaccine for cancer and infectious diseases. Cancer Gene Ther 20:2 (2012), 65–69.
151. Wold, W.S.M., Toth, K., Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Curr Gene Ther 13:6 (2013), 421–433.
152. Peng, Z., Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther 16:9 (2005), 1016–1027.
153. Wold, W.S.M., G. M, Adenoviruses. Fields Virology, vol. 1, 2013, Wolters Kluwer Health Lippincott Williams Wilkins, Philidelphia, 1345–1374.
154. Nemunaitis, J., Head and neck cancer: response to p53-based therapeutics. Head Neck 33:1 (2011), 131–134.
155. Roth, J.A., Adenovirus p53 gene therapy. Expert Opin Biol Ther 6:1 (2006), 55–61.
156. Senzer, N., Nemunaitis, J., A review of contusugene ladenovec (Advexin) p53 therapy. Curr Opin Mol Ther 11:1 (2009), 54–61.
157. Nemunaitis, J., Clayman, G., Agarwala, S.S., Biomarkers predict p53 gene therapy efficacy in recurrent squamous cell carcinoma of the head and neck. Clin Cancer Res 15:24 (2009), 7719–7725.
158. Tian, G., Liu, J., Zhou, J.S.R., Chen, W., Multiple hepatic arterial injections of recombinant adenovirus p53 and 5-fluorouracil after transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a pilot phase II trial. Anticancer Drugs 20:5 (2009), 389–395.
159. Ma, G., Shimada, H., Hiroshima, K., Tada, Y., Suzuki, N., Tagawa, M., Gene medicine for cancer treatment: commercially available medicine and accumulated clinical data in China. Drug Des Devel Ther 2 (2009), 115–122.
160. Shi, J., Zheng, D., An update on gene therapy in China. Curr Opin Mol Ther 11:5 (2009), 547–553.
161. Shirakawa, T., The current status of adenovirus-based cancer gene therapy. Mol Cells 25:4 (2008), 462–466.
162. Li, Y., Li, B., Li, C.J., Li, L.J., Key points of basic theories and clinical practice in rAd-p53 (Gendicine ™) gene therapy for solid malignant tumors. Expert Opin Biol Ther 15:3 (2015), 437–454.
163. Vaillancourt, M.T., Atencio, I., Quijano, E., Howe, J.A., Ramachandra, M., Inefficient killing of quiescent human epithelial cells by replicating adenoviruses: potential implications for their use as oncolytic agents. Cancer Gene Ther 12:8 (2005), 691–698.
164. Ferrari, R., Pellegrini, M., Horwitz, G.A., Xie, W., Berk, A.J., Kurdistani, S.K., Epigenetic reprogramming by adenovirus e1a. Science 321:5892 (2008), 1086–1088.
165. Vähä-Koskela, M.J., Heikkilä, J.E., Hinkkanen, A.E., Oncolytic viruses in cancer therapy. Cancer Lett 254:2 (2007), 178–216.
166. Ganly, I., Kirn, D., Eckhardt, G., A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res 6:3 (2000), 798–806.
167. Kim, J., Cho, J.Y., Kim, J.H., Jung, K.C., Yun, C.O., Evaluation of E1B gene-attenuated replicating adenoviruses for cancer gene therapy. Cancer Gene Ther 9:9 (2002), 725–736.
168. Nemunaitis, J., Ganly, I., Khuri, F., Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an EkD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res 60:22 (2000), 1B–55B.
169. Liu, T.C., Galanis, E., Kirn, D., Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol 4:2 (2007), 101–117.
170. Khuri, F.R., Nemunaitis, J., Ganly, I., et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 6:8 (2000), 879–885.
171. Yu, W., Fang, H., Clinical trials with oncolytic adenovirus in China. Curr Cancer Drug Targets 7:2 (2007), 141–148.
172. Chira, S., Jackson, C.S., Oprea, I., et al. Progresses towards safe and efficient gene therapy vectors. Oncotarget 6:31 (2015), 30675–30703.
173. DeWeese, T.L., van Li, S., der Poel, H., A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res 61:20 (2001), 7464–7472.
174. Small, E.J., Carducci, M.A., Burke, J.M., A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther 14:1 (2006), 107–117.
175. Fukuda, K., Abei, M., Ugai, H., E1A, E1B double-restricted replicative adenovirus at low dose greatly augments tumor-specific suicide gene therapy for gallbladder cancer. Cancer Gene Ther 16:2 (2008), 126–136.
176. Li, X., Zhang, Y.P., Kim, H.S., et al. Gene therapy for prostate cancer by controlling adenovirus E1a and E4 gene expression with PSES enhancer. Cancer Res 65:5 (2005), 1941–1951.
177. Kim, E., Kim, J.H., Shin, H.Y., et al. Ad-mTERT-delta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner. Hum Gene Ther 14:15 (2003), 1415–1428.
178. Rodriguez, R., Schuur, E.R., Lim, H.Y., Henderson, G.A., Simons, J.W., Henderson, D.R., Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 57:13 (1997), 2559–2563.
179. Nettelbeck, D.M., Rivera, A.A., Balagué, C., Alemany, R., Curiel, D.T., Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter. Cancer Res 62:16 (2002), 4663–4670.
180. Conrad, C., Miller, C.R., Ji, Y., et al. Delta24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization. Cancer Gene Ther 12:3 (2005), 284–294.
181. Smaill, F., Jeyanathan, M., Smieja, M., A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity. Sci Transl Med, 5(205), 2013, 205ra134.
182. McElrath, M.J., De Rosa, S.C., Moodie, Z., et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372:9653 (2008), 1894–1905.
183. Harro, C., Sun, X., Stek, J.E., Immunol, C.V.I., Safety and immunogenicity of the Merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene vaccines alone and in combination in healthy adults. Clin Vaccine 16:9 (2009), 1285–1292.
184. Buchbinder, S.P., Mehrotra, D.V., Duerr, A., Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372:9653 (2008), 1881–1893.
185. Mennechet, F.J.D., Tran, T.T.P., Eichholz, K., van Kremer, E.J., de Perre, P., Ebola virus vaccine: benefit and risks of adenovirus-based vectors. Expert Rev Vaccines 14:11 (2015), 1471–1478.
186. De Santis, O., Audran, R., Pothin, E., et al. Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. Lancet Infect Dis 16:3 (2016), 311–320.
187. Green, C.A., Scarselli, E., Sande, C.J., Chimpanzee adenovirus-and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults. Sci Transl Med, 7(300), 2015, 300ra126.
188. Milligan, I.D., Gibani, M.M., Sewell, R., Safety and immunogenicity of novel adenovirus type 26-and modified vaccinia ankara-vectored Ebola vaccines: clinical trial. JAMA 315:15 (2016), 1610–1623.
189. Zhou, Y., Sullivan, N.J., Immunology and evolvement of the adenovirus prime, MVA boost Ebola virus vaccine. Curr Opin Immunol 35 (2015), 131–136.
190. Zhu, F.C., Hou, L.H., Li, J.X., et al. Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet 385:9984 (2015), 2272–2279.
191. Hill, A.V., Reyes-Sandoval, A., O'Hara, G., et al. Prime-boost vectored malaria vaccines: progress and prospects. Hum Vaccin 6:1 (2010), 78–83.
192. Scallan, C.D., Tingley, D.W., Lindbloom, J.D., Toomey, J.S., Tucker, S.N., Immunol, C.V.I., An adenovirus-based vaccine with a double-stranded RNA adjuvant protects mice and ferrets against H5N1 avian influenza in oral delivery models. Clin Vaccine 20:1 (2013), 85–94.
193. Peters, W., Brandl, J.R., Lindbloom, J.D., Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-γ T cell responses in humans. Vaccine 31:13 (2013), 1752–1758.
194. Alexander, J., Ward, S., Mendy, J., Pre-clinical evaluation of a replication-competent recombinant adenovirus serotype 4 vaccine expressing influenza H5 hemagglutinin. Plos One, 7(2), 2012, e31177.
195. Chiuppesi, F., Vannucci, L., De Luca, A., et al. A lentiviral vector-based, herpes simplex virus 1 (HSV-1) glycoprotein B vaccine affords cross-protection against HSV-1 and HSV-2 genital infections. J Virol 86:12 (Jun 2012), 6563–6574.
196. Wei, C.J., Boyington, J.C., McTamney, P.M., et al. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 329:5995 (2010), 1060–1064.
197. Gray, G., Buchbinder, S., Duerr, A., Curr, A., Opin, H.I.V., Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine. Curr Opin HIV AIDS 5:5 (2010), 357–361.
198. Liu, J., O'Brien, K.L., Lynch, D.M., et al. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 457:7225 (2009), 87–91.
199. Hammer, S.M., Sobieszczyk, M.E., Janes, H., Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med 369:22 (2013), 2083–2092.
200. Walsh, S.R., Moodie, Z., Fiore-Gartland, A.J., Heterologous, H.I.V., Increases, T., Vaccination with 1 envelope sequences and heterologous adenovirus vectors cell responses to conserved regions: HVTN 083. J Infect Dis 213:4 (2016), 541–550.
201. Baden, L.R., Karita, E., Mutua, G., Assessment of the safety and immunogenicity of 2 novel vaccine platforms for HIV-1 prevention: trial. Ann Intern Med 164:5 (2016), 313–322.
202. Ewer, K., Rampling, T., Venkatraman, N., et al. Chimpanzee adenovirus Ebola vaccine boosted with MVA. N Engl J Med 374:17 (2016), 1635–1646.
203. Stanley, D.A., Honko, A.N., Asiedu, C., Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med 20:10 (2014), 1126–1129.
204. Deen, G.F., Knust, B., Broutet, N., et al. Ebola in semen of Ebola virus disease survivors-preliminary report. N Engl J Med, 2015, 1–7.
205. Varkey, J.B., Shantha, J.G., Crozier, I., Persistence of Ebola virus in ocular fluid during convalescence. N Engl J Med 372:25 (2015), 2423–2427.
206. Martínez, M.J., Salim, A.M., Hurtado, J.C., Kilgore, P.E., Ebola virus infection: overview and update on prevention and treatment. Infect Dis Ther 4:4 (2015), 365–390.
207. Biswas, S., Choudhary, P., Elias, S.C., Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure. Plos One, 9(9), 2014, e107903.
208. Mast, T.C., Kierstead, L., Gupta, S.B., International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine 28:4 (2009), 950–957.
209. Abbink, P., Lemckert, A.A.C., Ewald, B.A., Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol 81:9 (2007), 4654–4663.
210. Swenson, D.L., Wang, D., Luo, M., Immunol, C.V.I., Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. Clin Vaccine 15:3 (2008), 460–467.
211. Pratt, W.D., Wang, D., Nichols, D.K., Immunol, C.V.I., Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector. Clin Vaccine 17:4 (2010), 572–581.
212. Ledgerwood, J.E., Costner, P., Desai, N., A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine 29:2 (2010), 304–313.
213. Luo, J., Sun, M.H., Kang, Q., et al. Gene therapy for bone regeneration. Curr Gene Ther 5:2 (2005), 167–179.
214. Luther, G., Wagner, E.R., Zhu, G., et al. BMP-9 induced osteogenic differentiation of mesenchymal stem cells: molecular mechanism and therapeutic potential. Curr Gene Ther 11:3 (2011), 229–240.
215. Lamplot, J.D., Qin, J., Nan, G., et al. BMP9 signaling in stem cell differentiation and osteogenesis. Am J Stem Cells 2:1 (2013), 1–21.
216. Shenaq, D.S., Rastegar, F., Petkovic, D., et al. Mesenchymal progenitor cells and their orthopedic applications: forging a path towards clinical trials. Stem Cells Int, 2010, 2010, 519028.
217. Rastegar, F., Shenaq, D., Huang, J., et al. Mesenchymal stem cells: molecular characteristics and clinical applications. World J Stem Cells 2:4 (2010), 67–80.
218. Thomas, C.E., Ehrhardt, A., Kay, M.A., Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 4:5 (2003), 346–358.
219. Luu, H.H., Song, W.X., Luo, X., et al. Distinct roles of bone morphogenetic proteins in osteogenic differentiation of mesenchymal stem cells. J Orthop Res 25:5 (2007), 665–677.
220. Deng, Z.L., Sharff, K.A., Tang, N., et al. Regulation of osteogenic differentiation during skeletal development. Front Biosci 13 (2008), 2001–2021.
221. Chen, L., Jiang, W., Huang, J., et al. Insulin-like growth factor 2 (IGF-2) potentiates BMP-9-induced osteogenic differentiation and bone formation. J Bone Min Res 25:11 (2010), 2447–2459.
222. Liu, X., Qin, J., Luo, Q., et al. Cross-talk between EGF and BMP9 signalling pathways regulates the osteogenic differentiation of mesenchymal stem cells. J Cell Mol Med 17:9 (2013), 1160–1172.
223. Zhang, H., Wang, J., Deng, F., et al. Canonical Wnt signaling acts synergistically on BMP9-induced osteo/odontoblastic differentiation of stem cells of dental apical papilla (SCAPs). Biomaterials 39 (2015), 145–154.
224. Zhang, W., Deng, Z.L., Chen, L., et al. Retinoic acids potentiate BMP9-induced osteogenic differentiation of mesenchymal progenitor cells. PLoS One, 5(7), 2010, e11917.
225. Liao, J., Wei, Q., Zou, Y., et al. Notch signaling augments BMP9-induced Bone formation by promoting the osteogenesis-angiogenesis coupling process in mesenchymal stem cells (MSCs). Cell Physiol Biochem 41:5 (2017), 1905–1923.
226. Wang, J., Liao, J., Zhang, F., et al. Nel-Like Molecule-1 (Nell1) is regulated by bone morphogenetic protein 9 (BMP9) and potentiates BMP9-induced osteogenic differentiation at the expense of adipogenesis in mesenchymal stem cells. Cell Physiol Biochem 41:2 (2017), 484–500.
227. Reddi, A.H., Bone morphogenetic proteins: from basic science to clinical applications. J Bone Jt Surg Am 83-A:Suppl 1(Pt 1) (2001), S1–S6.
228. Cheng, H., Jiang, W., Phillips, F.M., et al. Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs). J Bone Jt Surg Am 85-A:8 (2003), 1544–1552.
229. Kang, Q., Song, W.X., Luo, Q., et al. A comprehensive analysis of the dual roles of BMPs in regulating adipogenic and osteogenic differentiation of mesenchymal progenitor cells. Stem Cells Dev 18:4 (2009), 545–559.
230. Kang, Q., Sun, M.H., Cheng, H., et al. Characterization of the distinct orthotopic bone-forming activity of 14 BMPs using recombinant adenovirus-mediated gene delivery. Gene Ther 11:17 (2004), 1312–1320.
231. Sakou, T., Bone morphogenetic proteins: from basic studies to clinical approaches. Bone 22:6 (1998), 591–603.
232. Einhorn, T.A., Lee, C.A., Bone regeneration: new findings and potential clinical applications. J Am Acad Orthop Surg 9:3 (2001), 157–165.
233. Barnes, G.L., Kostenuik, P.J., Gerstenfeld, L.C., Einhorn, T.A., Growth factor regulation of fracture repair. J Bone Min Res 14:11 (1999), 1805–1815.
234. Lieberman, J.R., Daluiski, A., Stevenson, S., et al. The effect of regional gene therapy with bone morphogenetic protein-2-producing bone-marrow cells on the repair of segmental femoral defects in rats. J Bone Jt Surg Am 81:7 (1999), 905–917.
235. Park, J., Ries, J., Gelse, K., et al. Bone regeneration in critical size defects by cell-mediated BMP-2 gene transfer: a comparison of adenoviral vectors and liposomes. Gene Ther 10:13 (2003), 1089–1098.
236. Govender, S., Csimma, C., Genant, H.K., et al. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Jt Surg Am 84-A:12 (2002), 2123–2134.
237. Boden, S.D., Kang, J., Sandhu, H., Heller, J.G., Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies. Spine (Phila Pa 1976) 27:23 (2002), 2662–2673.
238. Friedlaender, G.E., Perry, C.R., Cole, J.D., et al. Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J Bone Jt Surg Am 83-A:Suppl 1(Pt 2) (2001), S151–S158.
239. Johnsson, R., Strömqvist, B., Aspenberg, P., Randomized radiostereometric study comparing osteogenic protein-1 (BMP-7) and autograft bone in human noninstrumented posterolateral lumbar fusion: 2002 Volvo Award in clinical studies. Spine (Phila Pa 1976) 27:23 (2002), 2654–2661.
240. Dayoub, H., Dumont, R.J., Li, J.Z., et al. Human mesenchymal stem cells transduced with recombinant bone morphogenetic protein-9 adenovirus promote osteogenesis in rodents. Tissue Eng 9:2 (2003), 347–356.
241. Varady, P., Li, J.Z., Cunningham, M., et al. Morphologic analysis of BMP-9 gene therapy-induced osteogenesis. Hum Gene Ther 12:6 (2001), 697–710.
242. Paul, R., Haydon, R.C., Cheng, H., et al. Potential use of Sox9 gene therapy for intervertebral degenerative disc disease. Spine (Phila Pa 1976) 28:8 (2003), 755–763.
243. Mehta, V., Kang, Q., Luo, J., He, T.C., Haydon, R.C., Mass, D.P., Characterization of adenovirus-mediated gene transfer in rabbit flexor tendons. J Hand Surg Am 30:1 (2005), 136–141.
244. Bolt, P., Clerk, A.N., Luu, H.H., et al. BMP-14 gene therapy increases tendon tensile strength in a rat model of Achilles tendon injury. J Bone Jt Surg Am 89:6 (2007), 1315–1320.
245. Xiong, W., Goverdhana, S., Sciascia, S.A., Candolfi, M., Zirger, J.M., Barcia, C., Regulatable gutless adenovirus vectors sustain inducible transgene expression in the brain in the presence of an immune response against adenoviruses. J Virol 80:1 (2006), 27–37.
246. Xiong, W., Candolfi, M., Kroeger, K.M., et al. Immunization against the transgene but not the TetReduces expression from gutless adenoviral vectors in the brain. Mol Ther 16:2 (2008), 343–351.
247. Shi, C.X., Graham, F.L., Hitt, M.M., A convenient plasmid system for construction of helper-dependent adenoviral vectors and its application for analysis of the breast-cancer-specific mammaglobin promoter. J Gene Med 8:4 (2006), 442–451.
248. Gonzalez-Aparicio, M., Mauleon, I., Alzuguren, P., et al. Self-inactivating helper virus for the production of high-capacity adenoviral vectors. Gene Ther 18:11 (2011), 1025–1033.
249. Candolfi, M., Curtin, J., Xiong, W., Kroeger, K., Liu, C., Rentsendorj, A., Effective high-capacity gutless adenoviral vectors mediate transgene expression in human glioma cells. Mol Ther 14:3 (2006), 371–381.
250. Hsu, P.D., Lander, E.S., Zhang, F., Development and applications of CRISPR-Cas9 for genome engineering. Cell 157:6 (2014), 1262–1278.
251. Sternberg, S.H., Doudna, J.A., Expanding the biologist's toolkit with CRISPR-Cas9. Mol Cell 58:4 (2015), 568–574.
252. Khalil, D.N., Smith, E.L., Brentjens, R.J., Wolchok, J.D., The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol 13:5 (2016), 273–290.
253. Figueroa, J.A., Reidy, A., Mirandola, L., et al. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy. Int Rev Immunol 34:2 (2015), 154–187.